SEC Comment Letter 0000000000-24-008978 to Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX)
Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: Aug. 6, 2024 · CIK: 0001534120 · Accession: 0000000000-24-008978
AI Filing Summary & Sentiment
File numbers found in text: 001-37590
Letter
August 6, 2024 Christopher Sullivan Chief Financial Officer Avalo Therapeutics, Inc. 540 Gaither Road, Suite 400 Rockville, MD 20850 Re:Avalo Therapeutics, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 Amendment No. 1 to Form 10-Q for Fiscal Quarter Ended March 31, 2024 File No. 001-37590 Dear Christopher Sullivan: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Andrew Gibbons
Show Raw Text
August 6, 2024
Christopher Sullivan
Chief Financial Officer
Avalo Therapeutics, Inc.
540 Gaither Road, Suite 400
Rockville, MD 20850
Re:Avalo Therapeutics, Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
Amendment No. 1 to Form 10-Q for Fiscal Quarter Ended March 31, 2024
File No. 001-37590
Dear Christopher Sullivan:
We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Andrew Gibbons